Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)

Glenmark Launches Vancomycin Hydrochloride for Injection in the U.S. Market

April 2025 – New Jersey: Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., today announced the launch of Vancomycin Hydrochloride for Injection USP in the U.S. market. The product is available in 750 mg/vial, 1.25 g/vial, and 1.5 g/vial strengths, each supplied as a single-dose vial.

Glenmark’s product is bioequivalent and therapeutically equivalent to the reference listed drug from Mylan Laboratories Limited (NDA 209481), ensuring it meets the same quality and efficacy standards.

According to IQVIA™ sales data for the 12-month period ending January 2025, the U.S. market for Vancomycin Hydrochloride for Injection in these strengths recorded annual sales of approximately $39.3 million.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America at Glenmark Pharmaceuticals, said:
“We are excited to announce the launch of Vancomycin Hydrochloride for Injection USP in various vial strengths, adding another quality product to our institutional portfolio. This launch underscores our commitment to providing accessible and effective treatments to the healthcare system.”

The introduction of Vancomycin Hydrochloride for Injection expands Glenmark’s growing portfolio of institutional injectable products in the U.S., further reinforcing its position in the generic pharmaceutical space.